Finding 1057298 (2021-004)

Significant Deficiency Repeat Finding
Requirement
A
Questioned Costs
-
Year
2021
Accepted
2024-08-09

AI Summary

  • Core Issue: Payroll approvals are not consistently made by supervisors or knowledgeable individuals, risking improper federal grant payments.
  • Impacted Requirements: This finding violates 2 CFR 200.303, which mandates effective internal controls over federal awards.
  • Recommended Follow-Up: AAPT should ensure that payroll approvers are the actual supervisors or knowledgeable about employee activities, with changes expected by 04/01/2024.

Finding Text

Finding 2021-004: Payroll Significant Deficiency Federal Programs: Research and Development Cluster: 47.076 Criteria or Specific Requirement (Including Statutory, Regulatory, or Other Citation): As noted in 2 CFR 200.303 “The non-Federal entity must establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States or the “Internal Control Integrated Framework”, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).” Condition: Payroll approvals for individuals are not always made by individuals who are the employee’s supervisors or are otherwise knowledgeable about their level of effort during the payroll periods paid for. Cause: AAPT did not appropriately assign or ensure approval by payroll approvers based on who supervised or was otherwise knowledgeable of employee activity on federal grants. Effect or Potential Effect: Without an individual knowledgeable of an individual employee’s level of effort approving the time charged there is a greater risk that payroll payments are applied to a federal grant improperly, or leave is otherwise improperly omitted or overapplied to the individual’s leave balance. Questioned Costs: None noted. Identification as a Repeat Finding, if Applicable: 2020-004. Recommendation: We recommend that AAPT change the designated approver for certain employees for whom the designated approver is not the employee’s supervisor or is not otherwise aware of the employee’s work efforts. Views of Responsible Officials and Planned Corrective Actions: AAPT has made changes to correctly reflect the employee’s assigned supervisor based on the position and job duties of the employees. Anticipated Completion Date: 04/01/2024 Responsible Official: Michael Brosnan, CFO

Categories

Matching / Level of Effort / Earmarking Significant Deficiency

Other Findings in this Audit

  • 480849 2021-003
    Material Weakness Repeat
  • 480850 2021-005
    Significant Deficiency Repeat
  • 480851 2021-003
    Material Weakness Repeat
  • 480852 2021-005
    Significant Deficiency Repeat
  • 480853 2021-003
    Material Weakness Repeat
  • 480854 2021-005
    Significant Deficiency Repeat
  • 480855 2021-003
    Material Weakness Repeat
  • 480856 2021-004
    Significant Deficiency Repeat
  • 480857 2021-005
    Significant Deficiency Repeat
  • 480858 2021-003
    Material Weakness Repeat
  • 480859 2021-005
    Significant Deficiency Repeat
  • 480860 2021-006
    Significant Deficiency Repeat
  • 480861 2021-003
    Material Weakness Repeat
  • 480862 2021-005
    Significant Deficiency Repeat
  • 480863 2021-003
    Material Weakness Repeat
  • 480864 2021-004
    Significant Deficiency Repeat
  • 480865 2021-005
    Significant Deficiency Repeat
  • 480866 2021-003
    Material Weakness Repeat
  • 480867 2021-005
    Significant Deficiency Repeat
  • 480868 2021-003
    Material Weakness Repeat
  • 480869 2021-005
    Significant Deficiency Repeat
  • 480870 2021-003
    Material Weakness Repeat
  • 480871 2021-005
    Significant Deficiency Repeat
  • 480872 2021-003
    Material Weakness Repeat
  • 480873 2021-005
    Significant Deficiency Repeat
  • 480874 2021-003
    Material Weakness Repeat
  • 480875 2021-005
    Significant Deficiency Repeat
  • 480876 2021-003
    Material Weakness Repeat
  • 480877 2021-005
    Significant Deficiency Repeat
  • 480878 2021-005
    Significant Deficiency Repeat
  • 480879 2021-005
    Significant Deficiency Repeat
  • 480880 2021-003
    Material Weakness Repeat
  • 480881 2021-005
    Significant Deficiency Repeat
  • 480882 2021-005
    Significant Deficiency Repeat
  • 1057291 2021-003
    Material Weakness Repeat
  • 1057292 2021-005
    Significant Deficiency Repeat
  • 1057293 2021-003
    Material Weakness Repeat
  • 1057294 2021-005
    Significant Deficiency Repeat
  • 1057295 2021-003
    Material Weakness Repeat
  • 1057296 2021-005
    Significant Deficiency Repeat
  • 1057297 2021-003
    Material Weakness Repeat
  • 1057299 2021-005
    Significant Deficiency Repeat
  • 1057300 2021-003
    Material Weakness Repeat
  • 1057301 2021-005
    Significant Deficiency Repeat
  • 1057302 2021-006
    Significant Deficiency Repeat
  • 1057303 2021-003
    Material Weakness Repeat
  • 1057304 2021-005
    Significant Deficiency Repeat
  • 1057305 2021-003
    Material Weakness Repeat
  • 1057306 2021-004
    Significant Deficiency Repeat
  • 1057307 2021-005
    Significant Deficiency Repeat
  • 1057308 2021-003
    Material Weakness Repeat
  • 1057309 2021-005
    Significant Deficiency Repeat
  • 1057310 2021-003
    Material Weakness Repeat
  • 1057311 2021-005
    Significant Deficiency Repeat
  • 1057312 2021-003
    Material Weakness Repeat
  • 1057313 2021-005
    Significant Deficiency Repeat
  • 1057314 2021-003
    Material Weakness Repeat
  • 1057315 2021-005
    Significant Deficiency Repeat
  • 1057316 2021-003
    Material Weakness Repeat
  • 1057317 2021-005
    Significant Deficiency Repeat
  • 1057318 2021-003
    Material Weakness Repeat
  • 1057319 2021-005
    Significant Deficiency Repeat
  • 1057320 2021-005
    Significant Deficiency Repeat
  • 1057321 2021-005
    Significant Deficiency Repeat
  • 1057322 2021-003
    Material Weakness Repeat
  • 1057323 2021-005
    Significant Deficiency Repeat
  • 1057324 2021-005
    Significant Deficiency Repeat

Programs in Audit

ALN Program Name Expenditures
43.001 Science $41,592
47.049 Mathematical and Physical Sciences $23,501
47.076 Education and Human Resources $20,896